Sveriges mest populära poddar
BioCentury This Week
VetenskapLife Science

Ep. 127 - TeneoTwo, Lightspeed, Arch & The Distillery

29 min•6 juli 2022

AstraZeneca’s takeout of single-asset spinout TeneoTwo for $100 million up front is but the latest payout to shareholders in TeneoBio, who could stand to see even more upside in the years ahead, says Associate Editor Paul Bonanos on the latest edition of the BioCentury This Week podcast. Bonanos and the BioCentury editors also discuss how TeneoTwo investor Lightspeed Venture Partners has deepened its commitment to life sciences investing; Arch Venture Partners’ plans to deploy its new $3 billion venture fund; and the latest translational highlights from BioCentury’s Distillery and Translational in Brief sections. Plus: A preview of BioCentury's fall conference.

Reach us by sending a text

Fler avsnitt av BioCentury This Week

Visa alla avsnitt av BioCentury This Week
Ep. 357 - Deal-O-rama, Gilead and Tallon's U.K. vision
•29 min
Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN
•34 min
Ep. 355 - Capital market mood, Xenon data, Friedreich ataxia pipeline
•25 min
Ep. 354 - East-West Summit Takeaways
•26 min
Ep. 353 - Prasad Departure and Future of Fibrosis Therapies
•37 min
Ep. 352 - A Multipolar Biopharma World; Rare Disease Spotlight
•35 min
Ep. 351 - Gilead's Arcellx Buy. Plus: ctDNA as Surrogate Endpoint
•35 min
Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA
•26 min
Ep. 349 - Start-up Spotlight, Compounding Wegovy & Neuropysch
•34 min
Ep. 348 - Biotech's 2026 Catalysts. Plus: China's New Orphan Rules
•31 min

BioCentury This Week med BioCentury finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.